Find additional information about AlloSure below.
Healthcare Provider Brochure
Donor-Derived Cell-Free DNA (dd-cfDNA): An Emerging Biomarker of Allograft Health in Solid Organ Transplant Recipients. Download brochure.
Bloom RD., Bromberg JS, Poggio E, et al. Cell-free DNA and active rejection in kidney allografts. J Am Soc Nephrol 2017; 28:2221.
Bromberg JS, Brennan DC, Poggio E, et al. Biological variation of donor-derived cell-free DNA in renal transplant recipients: clinical implications. J Appl Lab Med 2017; 2:309.
Grskovic M, Hiller DJ, Eubank LA, et al. Validation of a clinical-grade assay to measure donor-derived cell-free DNA in solid organ transplant recipients. J Mol Diagn 2016;18:890.
Jordan SC, Bunnapradist S, Bromberg JS, et al. Donor-derived cell-free DNA identified antibody-mediated rejection in donor specific antibody positive kidney transplant recipients. Transplant Direct 2018; 4:e379.
Donor-Derived Cell-Free DNA is a Dynamic Biomarker of Active Rejection in Kidney Allografts. View poster.
Donor-Derived Cell-Free DNA Normal Range and Biological Variation Defined in a Reference Population. View poster.
Donor-Derived Cell-free DNA in Plasma increases with Rejection and Decreases after Treatment in Kidney Transplant Recipients. View poster.
Donor-Derived Cell-Free DNA Identifies Antibody-Mediated Rejection With Graft Injury in DSA-Positive Kidney Transplant Recipients. View poster.
Clinically Relevant Variation of Donor-Derived Cell-Free DNA During Longitudinal Surveillance of Renal Allografts. View poster.
Donor-Derived Cell-Free DNA Outperforms Serum Creatinine Changes for Identifying Kidney Transplant Rejection. View poster.
Repeat Kidney Transplant Patients with Active Rejection Have Elevated Donor-Derived Cell-Free DNA. View poster.
Donor-Derived Cell-free DNA Improves DSA-informed Diagnosis of ABMR in Kidney Transplant Patients. View presentation.
Donor-Derived Cell-Free DNA Identifies Antibody-Mediated Rejection with Graft Injury in DSA-Positive Kidney Transplant Recipients. View presentation.
AST/AJT Journal Club: Cell-Free DNA and Active Rejection in Kidney Allografts. View presentation.
ATC Seattle 2018 CareDx, Inc. Lunch Symposium. View presentation.
What you should know about using AlloSure
+ Samples collected in Streck Cell-Free DNA BCT® tubes with no additional processing or preparation required before shipping
+ Samples are run in-house at CareDx’s CLIA-certified and CAP-accredited clinical laboratory
+ Results reported within 72 hours of blood draw
AlloSure Performance Characteristics